Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Clinical Requirements Regarding In Silico Oncology

Share :
Published: 23 Jan 2009
Views: 11537
Rating:
Save
Professor Norbert Graf, Director of Oncology and Haematology Clinic, University of Saarland
Lecture from the European Union ICT BIO 2008 Conference (Oct. 23-24, 2008) on Clinical Requirements Regarding In Silico Oncology

Related Videos

Linvoseltamab induces deep and durable responses in patients with relapsed or...
Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA
Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma ( Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA )
24 Apr 2024
Multiple myeloma in a resource constrained setting
Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda
Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )
22 Feb 2024
Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and...
Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal
Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects ( Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal )
25 Jan 2024
Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma...
Dr Jonathan Friedberg - University of Rochester, Rochester, USA
Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy ( Dr Jonathan Friedberg - University of Rochester, Rochester, USA )
4 Jan 2024
Management of multiple myeloma in a resource-constrained setting
Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda
Management of multiple myeloma in a resource-constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )
3 Jan 2024
Significant clinical benefits observed with revumenib monotherapy in relapsed...
Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA
Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia ( Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA )
24 Dec 2023
Ide-cell enhances health-related quality of life for refractory multiple myeloma
Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium
Ide-cell enhances health-related quality of life for refractory multiple myeloma ( Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium )
24 Dec 2023
Synthetic biology and precision medicine in blood and gynaecological cancers
Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...
Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )
21 Dec 2023
Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B...
Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany
Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B-cell lymphoma ( Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany )
20 Dec 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation